Immunity, Cellular
Conditions
Keywords
Influenza, B cells, Antibodies, Vaccination
Brief summary
Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
Detailed description
IM Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
Interventions
DRUGInfluenza Vaccine
Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
Sponsors
Washington University School of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Able to understand and give informed consent 2. Capable of attending all study visits according to the study schedule. 3. Males or females between the ages of 18 to 50 (inclusive). 4. Are in good health, as determined by medical history and targeted physical exam related to this history. 5. Participants agree not to take any vaccines in the first 60 days after receipt of the influenza vaccine 6. The following laboratory values obtained within 14 days prior to entry.. * Absolute neutrophil count (ANC) ≥750 cells/mm3 * Hemoglobin ≥11.0 g/dL for men and ≥10.0 g/dL for women * Platelet count ≥100,000/mm3 * Creatinine clearance ≥60 mL/min estimated by the Cockcroft-Gault equation * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (SGPT) ≤5.0 times upper limit of normal (ULN) 7. Willing to: * give FNA specimens for the study. (even if he/she are not willing to give bone marrow aspirates (for any reason), they can be enrolled) * give bone marrow aspirates, but we cannot locate axillary lymph nodes * give both FNA and BMA specimens
Exclusion criteria
* 1\. History influenza vaccination for the last three years. 2\. Coagulopathy (primary or iatrogenic) which would contraindicate FNA 3\. Any history of allergy to eggs, chicken or gelatin or to any previous influenza vaccine 4\. Have an acute illness within 72 hours before vaccination. 5\. A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study. 6\. History of HIV infection, Hepatitis B or Hepatitis C infection 7\. History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). 8\. History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the study. 9\. Have taken oral or parenteral corticosteroids of any dose within 30 days before study vaccination. 10\. Have taken high-dose inhaled corticosteroids within 30 days before study vaccination. 11\. Autoimmune disorders; mild autoimmune disorders such as eczema is not exclusion after assessment by the investigator. 12\. Recipient of a blood products or immune globulin product within 42 days of the vaccination visit. 13\. Pregnant women and nursing mothers or women who are planning to become pregnant for the study duration. 14\. Have received any licensed live vaccine within 30 days or any licensed inactivated vaccine within 14 days prior to study vaccination. 15\. Have planned vaccination with any vaccine during first 60 days of study participation. 16\. Have received immunoglobulin or other blood products, with the exception of Rho D immunoglobulin, within 90 days prior to study vaccination. 17\. Have donated blood or blood products within 30 days before study vaccination, plan to donate blood at any time during the duration of subject study participation, or plan to donate blood within 30 days after the last blood draw. 18\. Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the percentage of subjects achieving seroconversion | 0 and day 28 | Change in serum hemagglutination-inhibition (HAI) antibody titers between day 0 to day 28 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine the frequency of vaccine-induced responses | Day7 | Frequency of vaccine-specific plasmablasts detected in blood at day 7 after vaccination |
Countries
United States
Outcome results
None listed